Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch on Radcliffe Cardiology:

Following the announcement of a partnership between Medtronic and CathWorks – firstly concerning the co-promotion of the FFRangio® System, and then a proposed acquisition – here Jason Weidman, Senior Vice President and President of Coronary and Renal Denervation, Medtronic and Ramin Mousavi, CEO, CathWorks, discuss the challenges that have constrained the wider adoption of traditional FFR, and how the FFRangio® System seeks to overcome them.

Discussion Points:

1. CathWorks – its growth and evolution to date
2. The co-promotion partnership between Medtronic and CathWorks
3. FFR in clinical practice and the challenges for wider adoption
4. Differences between FFRangio® System and traditional FFR
5. Clinical evidence for patient outcomes with the FFRangio® System
6. Accuracy and sensitivity of the FFRangio® System compared to traditional FFR
7. Potentially transformative and disruptive effects of the technology
8. Strategy for educating physicians of the technology
9. Further technological enhancements to drive widespread FFR adoption
10. Longer-term partnership between Medtronic and CathWorks

Location: Recorded remotely
Interviewer: Jonathan McKenna

The opinions expressed here are those of the interviewees and not necessarily of Radcliffe Cardiology.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "Medtronic and CathWorks Announce Co-promotion Partnership For FFR-based Technology For CAD" передвинте ползунок вправо